We are an innovation focused biotech company dedicated to delivering next-generation multispecific antibody therapeutics so more people with cancer and other serious diseases can live longer and improved lives.

Our clinically validated multispecific antibody platform has delivered a deep proprietary and partnered pipeline of promising clinical and preclinical drug product candidates.

The “plug-and-play” format of our Fcab® and mAb2® technology platforms enables rapid discovery of differentiated drug product candidates with a natural human antibody format that allows for a straightforward manufacturing process, favourable safety profile and strong biological potency.

In 2023, F-star was acquired by invoX Pharma, a fully integrated biopharmaceutical company, wholly owned by Sino Biopharm.

Stay up to date with F-star

Login or create a free user account to follow this company and see updates on your dashboard.

Create account